• HARIBABU JOTHULA SVAK Life Sciences, Gajularamaram, Hyderabad-500090, Telangana, India
  • SRINIVASU NAVULURI Vignan's Foundation for Science, Technology and Research (Deemed to be University), Guntur-522213, Andhra Pradesh, India
  • NAVEEN REDDY MULAKAYALA SVAK Life Sciences, Gajularamaram, Hyderabad-500090, Telangana, India



Analytical method development, Cyclophosphamide, and its related substances, Forced degradation studies, and Stability indicating


Objective: The current study aimed to develop a simple, sensitive, and precise high-performance liquid chromatographic (HPLC) method for estimating cyclophosphamide and its related substances, as well as to implement the developed method in a capsule product.

Methods: Method development was performed using various solvent and buffer-solvent ratios at different flow rates for better resolution and to decrease the run time. The developed method was validated in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines. The developed method was implemented to estimate the amount of cyclophosphamide and its related substances.

Results: Chromatographical conditions were optimised, and the best chromatographical conditions with adequate resolution for cyclophosphamide and its related substances were achieved using the enable X-Bridge C18 column, using a mobile phase combination of phosphate buffer pH 7.0, water, methanol, and acetonitrile at a flow rate of 0.5 ml/min. The detection was monitored at a wavelength of 200 nm. The developed method was validated for system suitability, specificity, limit of detection (LOD), limit of quantitation (LOQ), linearity, precision, accuracy and robustness. The results indicate that the method was sensitive and could detect and quantify lower levels of cyclophosphamide and its related substances. The linearity range was from LOQ to 150 %, and a correlation coefficient ranging from 0.9987 to 0.9999 indicates that at this concentration range, substances were highly linear. This was further supported by satisfactory forced degradation studies.

Conclusion: The developed analytical method is simple, precise, and reproducible and thus can be used for the stability-indicating analysis of cyclophosphamide and its related substances in pharmaceutical formulations.


Download data is not yet available.


Flowers JL, Ludeman SM, Gamcsik MP, Colvin OM, Shao KL, Boal JH. Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. Cancer Chemother Pharmacol. 2000;45(4):335-44. doi: 10.1007/s002800050049, PMID 10755323.

Nagulu M, kiran UV, Rama Krishna D. Development of rapid and simple HPLC method for the determination of cyclophospamide in human serum. Asian J Pharm Clin Res. 2009;2(3):34-8.

O’Connor PM, Wassermann K, Sarang M, Magrath I, Bohr VA, Kohn KW. Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt’s lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res. 1991;51(24):6550-7. PMID 1742728.

Islam S, Vedigounder M. Development of validation of a rapid and simple analytical separation method for anticancer alkylating agents using an application of total error concept. J Res Pharm. 2022;26(2):431-43.

Dhakhane VD, Ubale MB. Development and validation of a reverse-phase high-performance liquid chromatographic method for the estimation of cyclophosphamide in bulk drug. Int J Pharm Pharm Sci. 2013;5(2):184-7.

Siddappa K, Prashant CH, Sunilkumar BM, Nagabhushana MM. Development and validation of spectrophotometric method for the determination of cyclophosphamide in bulk drug and its pharmaceutical dosage form. Int J Pharm Pharm Sci. 2013;5(4):597-600.

Sahu MK, Dubey N, Pandey R, Shukla SS, Gidwani B. Formulation, evaluation, and validation of microspheres of cyclophosphamide for topical delivery. Pharmacophore. 2023;14(1):1-8. doi: 10.51847/e4GvuoN96z.

Chetan C, Chanakya T, Chetan C. Quantification of cyclophosphamide impurities in cyclophosphamide drug substance and formulations by ion chromatography. Int J Sci Res. 2021;10(4):306-12.

Radosław C, Jarosław JH, Agata KW, Jacek N. Development and validation of SPE-HPLC-MS/MS method for determining cyclophosphamide in surface waters. Pol J Environ Stud. 2014;23(5):1537-45.

Islam S, Murugan V, Kumari P, Shabbhag N. Development and validation of a liquid chromatographic method for the quantification of related compounds in cyclophosphamide. Pharm Anal Acta. 2018;9(9):595-9.

Shivakumar G, Dwivedi J. Identification of degradation products in cyclophosphamide API by LC-QTOF mass spectrometry. J Liq Chromatogr Relat Technol. 2015;38(2):190-5. doi: 10.1080/10826076.2014.896817.

Attie de Castro F, Scatena S, Cass QB, Simoes BP, Lanchote VL. Analysis of cyclophosphamide and carboxyethylphosphoramide mustard enantiomers in human plasma and application to clinical pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;971:14-9. doi: 10.1016/j.jchromb.2014.09.008, PMID 25261835.

Shanker Kasudhan K, Patial A, Mehra N, Verma Attri S, Malhotra P, Pattanaik S. Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramide mustard quantification with liquid chromatography-mass spectrometry in a single run human plasma samples: a rapid and sensitive method development. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1198:123228. doi: 10.1016/j.jchromb.2022.123228, PMID 35385800.

Harahap Y, Steven S, Suryadi H. Development and validation of a UPLC-MS/MS method with volumetric absorptive microsampling to quantitate cyclophosphamide and 4-hydroxycyclophosphamide. Front Pharmacol. 2022;13:928721. doi: 10.3389/fphar.2022.928721, PMID 36034779.

Yesi H, Yahdiana H, Herman S. Development and validation method of cyclophosphamide and 4-hydroxycyclophosphamide with 4-hydroxycyclophosphamide-d as internal standard in dried blood spots using UPLC-MS/MS. Int J Appl Pharm. 2021;13(2):148-52.

Kerbusch T, Huitema AD, Jeuken MJ, Derraz J, Tibben MM, Beijnen JH. Simultaneous determination of ifosfamide and its metabolite Ifosforamide mustard in human plasma by high-performance liquid chromatography. Journal of Liquid Chromatography & Related Technologies. 2000;23(19):2991-3010. doi: 10.1081/JLC-100101838.

Ahmed M, Usman M, Madni A, Zubai M. A fast and simple HPLC-UV method for simultaneous determination of three anticancer agents in plasma of breast cancer patients and its application to clinical pharmacokinetics. Afr J Pharm. 2011;5(7):915-22.

The international council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). ICH guidance on method validation; validation of analytical procedures text and methodology. Geneva. Vol. Q2; 2005. Available from: [Last accessed on 16 Sep 2023].

Sanson AL, Silva SC, Martins MC, Giusti Paiva A, Maia PP, Martins I. Liquid-liquid extraction combined with high-performance liquid chromatography-diode array-ultra-violet for simultaneous determination of antineoplastic drugs in plasma. Braz J Pharm Sci. 2011;47(2):363-71. doi: 10.1590/S1984-82502011000200017.

Prasad V, Pranothi M, Diwan VP, Kishore C. Development of HPLC method for the identification related substances and assay of zoledronic acid in a tablet dosage form. Br Biomed Bull. 2013;4(5):44-55.

Somasekhar V. Optimization and validation of an RP-HPLC method for the estimation of 6-mercaptopurine in bulk and pharmaceutical formulations. Braz J Pharm Sci. 2014;50(4):793-7. doi: 10.1590/S1984-82502014000400015.



How to Cite

JOTHULA, H., S. NAVULURI, and N. R. MULAKAYALA. “STABILITY BASED HPLC METHOD FOR CYCLOPHOSPHAMIDE RELATED SUBSTANCES IN FINISHED DRUG PRODUCTS: DEVELOPMENT AND VALIDATION”. International Journal of Current Pharmaceutical Research, vol. 16, no. 3, May 2024, pp. 42-51, doi:10.22159/ijcpr.2024v16i3.4061.



Original Article(s)